AlphAIAlphAI — Financial news for AI agents
hcplive.comSEP 302 min read$LLY

EASD 2026: EloraTZP Bests Tirzepatide on Weight Loss, A1C in Type 2 Diabetes

EloraTZP, a combination of eloralintide and tirzepatide, showed superior weight loss (23.3%) and A1C reduction (2.9%) in a phase 2b trial for type 2 diabetes. Lilly plans phase 3 trials by late 2026. The drug targets multiple hormonal pathways, with common mild/moderate gastrointestinal side effects.

Original reporting
hcplive.com
Published Sep 30, 2026, 10:27 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Oct 1, 2026, 1:15 AM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
About AlphAI AI DeskScoring methodologyReport an issue
EASD 2026: EloraTZP Bests Tirzepatide on Weight Loss, A1C in Type 2 Diabetes — source image
Source · hcplive.com
Decision brief

The 30-second read

$LLYBullishHigh
01

Why it matters

The data suggests a meaningful efficacy advantage over tirzepatide alone, positioning Lilly for a differentiated product in a large market.

02

Market read

First disclosure of compelling Phase 2b results could move Lilly stock and influence the obesity/diabetes therapeutic landscape.

03

What to watch

Potential market impact depends on regulatory pathway and pricing strategy for the combination therapy.

Relevance 9/10Novelty 9/10Timing: same‑day release

Background

Eli Lilly presented new Phase 2b results for EloraTZP at the EASD 2026 meeting, highlighting its dual‑hormone mechanism.

Company-level read

Ticker impact

$LLYBullishHigh confidence
Context

Phase 2b data shows EloraTZP achieved up to 23.3% weight loss and 2.9% A1C reduction, outperforming tirzepatide alone.

Expected impact

likely upside as market prices in the stronger weight‑loss and A1C results

Evidence & confidence

First‑time disclosure of robust Phase 2b outcomes for a novel amylin‑GLP‑1 combo, with Lilly planning Phase 3 later this year.

Market effects

Sector

May boost the broader obesity/diabetes therapeutic sector and increase competitive pressure on Novo Nordisk.

Regional

U.S. biotech stocks could see modest gains as the data underscores pipeline strength.

Global

International investors tracking obesity treatments may re‑price exposure to related companies.

Counterpoint

What could challenge this read

If safety concerns or later‑stage trial failures emerge, the initial enthusiasm could reverse quickly.

Key entities

  • company
    Eli Lilly and Company

    Pharmaceutical developer of the EloraTZP combination.

  • company
    Novo Nordisk

    Competitor with its own amylin‑GLP‑1 combo (CagriSema).

Read at source← All news

Related articles

SEP 30
$LLYMedAI 8/10

Retatrutide Yields Significant Weight Loss in T2D

Eli Lilly's phase 3 TRIUMPH-2 study shows retatrutide, a triple hormonal agonist, achieved significant weight loss (up to 20.8%) and glycemic improvements in adults with type 2 diabetes (T2D) and obesity. The study, presented at EASD 2026, involved 1152 participants and showed retatrutide's efficacy estimand exceeded 20% weight reduction, a threshold not previously reached in T2D patients.

medscape.com3 min
SEP 30
$LLYHighAI 9/10

Eli Lilly's Foundayo Shows Cardiovascular Benefits in Phase 3 Tr

Eli Lilly (LLY) reported positive Phase 3 trial results for Foundayo, showing cardiovascular benefits in type 2 diabetes patients. The drug matched insulin glargine in preventing major adverse cardiovascular events while improving A1C levels and weight reduction. Foundayo reduced serious cardiovascular risks by 16%, cardiovascular mortality by 53%, and overall mortality by 57%.

gurufocus.com2 min
SEP 30
$LLYMedAI 8/10

Lilly's oral GLP-1, Foundayo (orforglipron), demonstrated cardiovascular safety alongside sustained A1C reduction and weight loss in its largest and longest type 2 diabetes study | Eli Lilly and Company

Eli Lilly's oral GLP-1 drug, Foundayo (orforglipron), showed cardiovascular safety and sustained A1C reduction in the ACHIEVE-4 trial. Participants had a 16% lower risk of MACE-4 and 23% lower risk of MACE-3 vs. insulin glargine. Foundayo also demonstrated weight loss and improved cardiovascular risk factors. The trial involved 2,749 adults with type 2 diabetes and obesity or overweight.

investor.lilly.com3 min
SEP 30
$LLYHighAI 8/10

Weight-loss-drug makers unveil new data and deals

Eli Lilly presented Phase 3 data for retatrutide, showing 23% weight loss and significant blood sugar reductions. Novo Nordisk and Genentech licensed weight-loss molecules from Jiangsu Hengrui and Hanmi Pharmaceuticals, respectively, for upfront payments of $300M and $190M. Roche abandoned its obesity drug, emugrobart, after Phase 2 trial failures.

acs.org3 min
SEP 30
$LLYHighAI 8/10

Lilly's oral GLP-1, Foundayo (orforglipron), demonstrated cardiovascular safety alongside sustained A1C reduction and weight loss in its largest and longest type 2 diabetes study

Eli Lilly's Foundayo (orforglipron) showed a 16% lower risk of major cardiovascular events and 23% lower risk of cardiovascular death, heart attack, or stroke compared to insulin glargine in the ACHIEVE-4 trial. The drug also demonstrated improvements in A1C, weight, and other cardiometabolic health measures. Lilly plans to present these results at the EASD meeting and publish them in The Lancet.

prnewswire.com2 min
SEP 30
$LLYMedAI 9/10

Eli Lilly Diabetes Drug Spurs Record Weight Loss in Trials

Eli Lilly's experimental weight-loss drug retatrutide showed significant results in trials, with participants losing up to 60-70 pounds. The drug also improved blood-sugar levels, with some diabetes patients achieving remission. The company plans to seek FDA approval next year, according to trial results published in the Lancet and the New England Journal of Medicine.

newser.com2 min